Innoviva, Inc.
- INVA
- NASDAQ
- Biotechnology
- Respiratory Pharmaceuticals
- Inhaled Combination Therapies
$21.08
Today +1.44%Quote Oct 19, 2026, 08:00 PM UTC
−0.28%over the last month
Max drawdown −4.3%From 1-month high −1.7%3 months −2.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Innoviva
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments.
Where the money comes from
Q2 2026 revenue $119.6M
- Royalty$56.3M47.1%
- Product$51.8M43.3%
- License And Other Revenue$11.5M9.6%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
159
Founded
1996
Market value
$1.52B
Quote Oct 19
Floor
$21.03
0.2% below price
Resistance
$21.26
0.9% above price
Price vs analyst targets
10 analysts
Lowest target
$34.00Highest target
$42.00
$34.00Highest target
$42.00
- Price $21.08
- Average target $38.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 80% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about INVAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free